Design and optimization strategies for the development of new drugs that treat chronic kidney disease-Reference-Cited by-同舟云学术

Design and optimization strategies for the development of new drugs that treat chronic kidney disease

Published:2019-11-18 Issue:1 Volume:15 Page:101-115
ISSN:1746-0441
Container-title:Expert Opinion on Drug Discovery
language:en
Short-container-title:Expert Opinion on Drug Discovery

Author:

Ramos Adrián M.¹²,Fernández-Fernández Beatriz²³,Pérez-Gómez María Vanessa²⁴,Carriazo Julio Sol María³,Sanchez-Niño María Dolores¹²,Sanz Ana¹²,Ruiz-Ortega Marta²⁵,Ortiz Alberto²⁴⁶

Affiliation:

1. Laboratory of Nephrology and Hypertension, Instituto de Investigación Sanitaria-Fundación Jiménez Díaz (IIS-FJD), School of Medicine, Universidad Autónoma de Madrid, Madrid, Spain

2. Red de Investigación Renal (REDINREN), Instituto de Salud Carlos III, Madrid, Spain

3. Nephrology, Instituto de Investigación Sanitaria-Fundación Jiménez Díaz (IIS-FJD), School of Medicine, Universidad Autónoma de Madrid, Madrid, Spain

4. Instituto de Investigación Sanitaria-Fundación Jiménez Díaz (IIS-FJD), School of Medicine, Universidad Autónoma de Madrid, Madrid, Spain

5. Laboratory of Renal and Vascular Pathology and Diabetes, Instituto de Investigación Sanitaria-Fundación Jiménez Díaz (IIS-FJD), School of Medicine, Universidad Autónoma de Madrid and Cellular Biology in Renal Diseases Laboratory, Universidad Autónoma de Madrid, Madrid, Spain

6. Fundación Renal Iñigo Álvarez de Toledo IRSIN C/José Abascal, Madrid, Spain

Publisher

Informa UK Limited

Subject

Drug Discovery

Link

https://www.tandfonline.com/doi/pdf/10.1080/17460441.2020.1690450

Reference154 articles.

1. The Spanish Society of Nephrology (SENEFRO) commentary to the Spain GBD 2016 report: Keeping chronic kidney disease out of sight of health authorities will only magnify the problem

2. Forecasting life expectancy, years of life lost, and all-cause and cause-specific mortality for 250 causes of death: reference and alternative scenarios for 2016–40 for 195 countries and territories

3. Clarifying the concept of chronic kidney disease for non-nephrologists

4. Meso-American nephropathy: what we have learned about the potential genetic influence on chronic kidney disease development*

5. CKD hotspots around the world: where, why and what the lessons are. A CKJ review series

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Management of Microcomplications of Diabetes Mellitus: Challenges, Current Trends, and Future Perspectives in Treatment;Biomedicines;2024-08-28

2. The interaction between klotho protein and epigenetic alteration in diabetes and treatment options;Journal of Diabetes & Metabolic Disorders;2024-02-14

3. Ootheca mantidis mitigates renal fibrosis in mice by the suppression of apoptosis via increasing the gut microbe Akkermansia muciniphila and modulating glutamine metabolism;Biomedicine & Pharmacotherapy;2023-10

4. Discovery and Design of Novel Cyclic Peptides as Specific Inhibitors Targeting CCN2 and Disrupting CCN2/EGFR Interaction for Kidney Fibrosis Treatment;Journal of Medicinal Chemistry;2023-06-06

5. Dapaglifozin on Albuminuria in Chronic Kidney Disease Patients with FabrY Disease: The DEFY Study Design and Protocol;Journal of Clinical Medicine;2023-05-26